Fulcrum Pharmaceuticals

Fulcrum Pharmaceuticals applies computational chemistry, structural biology, and thermodynamics to accelerate the design and development of pharmaceutical products. Founded in 2002, Fulcrum has developed a series of proprietary lead compounds targeting inflammatory diseases, osteoporosis, infectious diseases, and oncology. The portfolio includes small molecule inhibitors of receptors and enzymes, small molecule mimetics of antibodies and receptors, and "adaptive" anti-infective drugs (capable of overcoming drug resistance). Fulcrum's strategy is to out-license parts of its pipeline while retaining selected compounds for internal development.